Tiffany Hurd [Image courtesy of CB Therapeutics]
The synthetics biology company CB Therapeutics recently named Tiffany Hurd as its new business development lead.At Carlsbad, California-based CB Therapeutics, Hurd will focus on creating business partnerships with companies in the psychedelic, cannabinoid and food tech industries.
In May, CB Therapeutics won a patent covering the use of microorganisms to produce psychedelic tryptamines and their analogs, including psilocybin and other molecules.
In the following interview, Hurd explains the psychedelics’ role in her transition from working in senior neurology and neuroscience positions, and why she believes psychedelics could potentially help improve mental health at large.
The responses have been lightly edited.
Drug Discovery & Development: Psychedelics are getting a lot of attention as potential therapies for condition…